Neurobiological potential of astragaloside IV and prospects for its use in the treatment of Alzheimer’s disease

Close metadata

Recommended articles:

Glymphatic dysfunction and sleep disorders: indirect effects on Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):7-12

Ginkgolide B: mechanisms of neurobiological effects, prospects for use in the therapy of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):22-27

Comparative characteristics of neuropsychological and neurometabolic changes in patients with Alzheimer’s disease and vascular cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):17-24

Impairment of attention and executive functions in chronic cerebrovascular disease and Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):25-32

Assessment of the significance of dilated perivascular spaces and nocture arterial hypertension in the development of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):33-40

EEG changes in patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):72-76

The role of astrocytes, circadian rhythms and light pollution in the pathogenesis of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):20-25

Immunological and neuroanatomic markers of the clinical dynamics of MCI and pre-MCI. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8):81-91

Mortality from cerebrovascular diseases in the Russian Federation before and during the COVID-19 epidemy: regional differences. Russian Journal of Preventive Medicine. 2024;(4):12-17

The role of mitochondrial dysfunction in the stabilization of the glaucomatous process. Russian Annals of Ophthalmology. 2024;(4):49-58

The review presents an analysis of experimental data on the study of the neurobiological effects of astragaloside IV, which can be used in the treatment of Alzheimer’s disease. Astragaloside IV is a cycloartan triterpene saponin, which is found in the roots of membranous milk vetch (Astragalus membranaceus (Fisch. ex Link) Bunge) and has a very wide range of pharmacological activity. In recent years, this compound has attracted attention due to its diverse neurobiological effects. Studies have shown the ability of astragaloside IV to modulate microglial activity. The protective effect of this saponin on neurons from the effects of glutamate-induced neurotoxicity has been demonstrated. In PC12 cells, astragaloside IV is shown to be able to resolve various types of mitochondrial dysfunction and inhibit endoplasmic reticulum stress. This compound is also a PPARγ agonist. In vivo experiments have shown that the test substance effectively protects synapses as well as improves cognitive functions, including memory and learning. It is concluded that astragaloside IV, apparently, may be used in the future as a multi-purpose complex therapy for Alzheimer’s disease.

Keywords:

astragaloside IV

Alzheimer’s disease

microglia activation

mitochondrial dysfunction

endoplasmic reticulum stress

memory

learning

Authors:

Berezutsky M.A.

Razumovsky Saratov State Medical University

ORCID: 0000-0003-0433-8247

Durnova N.A.

V.I. Razumovsky Saratov State Medical University;
I.M. Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0003-4628-9519

Kurchatova M.N.

V.I. Razumovsky Saratov State Medical University

ORCID: 0000-0003-4432-5555

Matvienko U.A.

V.I. Razumovsky Saratov State Medical University

ORCID: 0000-0002-1714-9165

Received:

03.09.2024

Accepted:

01.11.2024

List of references:

Gavrilova SI, Kolykhalov IV, Kulik AS, et al. Clinical experience of the use of memantal in patients with moderate and severe Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(2):52-57. (In Russ.). https://doi.org/10.17116/jnevro20161162152-57
Lane CA, Hardy J, Schott JM. Alzheimer’s disease. Eur J Neurol. 2018;25(1):59-70. https://doi.org/10.1111/ene.13439
Kovalenko EA, Makhnovich EV, Osinovskaya NA, et al. Focused ultrasound as a non-invasive method with therapeutic potential in patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(10):38-45. (In Russ.). https://doi.org/10.17116/jnevro202212210138
Sachan A, Singh S, Singh HK, et al. An experimental study to evaluate the effect of mucuna pruriens on learning and memory in mice. Int J Innov Sci Res. 2015;4(4):144-148.
Costa IM, Lima FO, Fernandes LC, et al. Astragaloside IV supplementation promotes a neuroprotective effect in experimental models of neurological disorders: a systematic review. Curr Neuropharmacol. 2019;17(7):648-665. https://doi.org/10.2174/1570159X16666180911123341
Yao J, Liu J, He Y, et al. Systems pharmacology reveals the mechanism of Astragaloside IV in improving immune activity on cyclophosphamide-induced immunosuppressed mice. J Ethnopharmacol. 2023;313:116533. https://doi.org/10.1016/j.jep.2023.116533
Li L, Hou X, Xu R, et al. Research review on the pharmacological effects of astragaloside IV. Fundam Clin Pharmacol. 2017;31(1):17-36. https://doi.org/10.1111/fcp.12232
Zhou L, Li M, Chai Z, et al. Anticancer effects and mechanisms of astragaloside-IV. Oncol Rep. 2023;49(1):1-15. https://doi.org/10.3892/or.2022.8442
Berezutskii MA, Yakubova LR, Durnova NA, et al. Pharmacological properties of preparations based on Astragalus extract. Pharmaceutical Chemistry Journal. 2020;54(4):372-376. https://doi.org/10.1007/s11094-020-02206-x
Hsieh HL, Liu SH, Chen YL, et al. Astragaloside IV suppresses inflammatory response via suppression of NF-κB, and MAPK signalling in human bronchial epithelial cells. Arch Physiol Biochem. 2022;128(3):757-766. https://doi.org/10.1080/13813455.2020.1727525
Yuan F, Yang Y, Liu L, et al. Research progress on the mechanism of astragaloside IV in the treatment of asthma. Heliyon. 2023;9(11):e22149. https://doi.org/10.1016/j.heliyon.2023.e22149
Qu C, Tan X, Hu Q, et al. A systematic review of astragaloside IV effects on animal models of diabetes mellitus and its complications. Heliyon. 2024;10(5):e26863. https://doi.org/10.1016/j.heliyon.2024.e26863
Indu P, Arunagirinathan N, Rameshkumar MR, et al. Antiviral activity of astragaloside II, astragaloside III and astragaloside IV compounds against dengue virus: computational docking and in vitro studies. Microb Pathog. 2021;152:104563. https://doi.org/10.1016/j.micpath.2020.104563
Berezutsky MA, Durnova NA, Vlasova IA. Experimental and clinical studies of mechanisms of the anti-aging effects of chemical compounds in Astragalus membranaceus (review). Advances in Gerontology= Uspekhi Gerontologii. 2019;32(5):702-710.
Stępnik K, Kukula-Koch W. In silico studies on triterpenoid saponins permeation through the blood–brain barrier combined with postmortem research on the brain tissues of mice affected by Astragaloside IV Administration. Int J Mol Sci. 2020;21(7):2534. https://doi.org/10.3390/ijms21072534
Chen G, Ding H, Liu Y, et al. Study on phase I clinical tolerance of the astragalus a glycoside of glucose injection (Chin). Pharmacol. Clinics Chin Mat Medica. 2012;28:134-136.
Heppner FL, Ransohoff RM., Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015;16(6):358-372. https://doi.org/10.1038/nrn3880
Prokop S, Miller KR, Heppner FL. Microglia actions in Alzheimer’s disease. Acta Neuropathol. 2013;126(4):461-477. https://doi.org/10.1007/s00401-013-1182-x
Malashenkova IK, Hailov NA, Krynskiy SA, et al. Levels of proinflammatory cytokines and VEGF in patients with Alzheimer’s disease and mild cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(3):39-43. (In Russ.). https://doi.org/10.17116/jnevro20161163139-43
He L, Sun J, Miao Z, et al. Astragaloside IV attenuates neuroinflammation and ameliorates cognitive impairment in Alzheimer’s disease via inhibiting NF-κB signaling pathway. Heliyon. 2023;9(2):e13411. https://doi.org/10.1016/j.heliyon.2023.e13411
Liu HS, Shi HL, Huang F, et al. Astragaloside IV inhibits microglia activation via glucocorticoid receptor mediated signaling pathway. Sci Rep. 2016;6:19137. https://doi.org/10.1038/srep19137
Li C, Yang F, Liu F, et al. NRF2/HO-1 activation via ERK pathway involved in the anti-neuroinflammatory effect of Astragaloside IV in LPS induced microglial cells. Neurosci Lett. 2018;666:104-110. https://doi.org/10.1016/j.neulet.2017.12.039
Yu J, Guo M, Li Y, et al. Astragaloside IV protects neurons from microglia-mediated cell damage through promoting microglia polarization. Folia Neuropathol. 2019;57(2):170-181. https://doi.org/10.5114/fn.2019.86299
Chen F, Yang D, Cheng XY, et al. Astragaloside IV ameliorates cognitive impairment and neuroinflammation in an oligomeric Aβ induced Alzheimer’s disease mouse model via inhibition of microglial activation and NADPH oxidase expression. Biol Pharm Bull. 2021;44(11):1688-1696. https://doi.org/10.1248/bpb.b21-00381
Feng YS, Tan ZX, Wu LY, et al. The involvement of NLRP3 infammasome in the treatment of Alzheimer’s disease. Ageing Res Rev. 2020;64:101192. https://doi.org/10.1016/j.arr.2020.101192
Song MT, Ruan J, Zhang RY, et al. Astragaloside IV ameliorates neuroinflammation-induced depressive-like behaviors in mice via the PPARγ/NF-κB/NLRP3 inflammasome axis. Acta Pharmacol Sin. 2018;39(10):1559-1570. https://doi.org/10.1038/aps.2017.208
Huijbers W, Mormino EC, Schultz AP, et al. Amyloid-β Deposition in Mild Cognitive Impairment Is Associated with Increased Hippocampal Activity, Atrophy and Clinical Progression. Brain. 2015;138(Pt 4):1023-1035.
Huijbers W, Schultz AP, Papp KV, et al. Tau Accumulation in Clinically Normal Older Adults Is Associated with Hippocampal Hyperactivity. J Neurosci. 2019;39(3):548-556. https://doi.org/10.1523/JNEUROSCI.1397-18.2018
Ghatak S, Dolatabadi N, Trudler D, et al. Mechanisms of hyperexcitability in Alzheimer’s disease hiPSC-derived neurons and cerebral organoids vs isogenic controls. Elife. 2019;8:e50333. https://doi.org/10.7554/eLife.50333
Yue R, Li X, Chen B, et al. Astragaloside IV attenuates glutamate-induced neurotoxicity in PC12 cells through Raf-MEK-ERK pathway. PLoS One. 2015;10(5):e0126603. https://doi.org/10.1371/journal.pone.0126603
Misrani A, Tabassum S, Yang L. Mitochondrial dysfunction and oxidative stress in Alzheimer’s disease. Front Aging Neurosci. 2021;13:617588. https://doi.org/10.3389/fnagi.2021.617588
Llanos-Gonzalez E, Henares-Chavarino AA, Pedrero-Prieto CM, et al. Interplay Between Mitochondrial Oxidative Disorders and Proteostasis in Alzheimer’s Disease. Front Neurosci. 2020;13:1444. https://doi.org/10.3389/fnins.2019.01444
Rak M, Benit P, Chretien D, et al. Mitochondrial cytochrome c oxidase deficiency. Clin Sci (Lond). 2016;130(6):393-407. https://doi.org/10.1042/CS20150707
Elgenaidi IS, Spiers JP. Regulation of the phosphoprotein phosphatase 2A system and its modulation during oxidative stress: A potential therapeutic target? Pharmacol Ther. 2019;198:68-89. https://doi.org/10.1016/j.pharmthera.2019.02.011
Toral-Rios D, Pichardo-Rojas PS, Alonso-Vanegas M, et al. GSK3β and Tau Protein in Alzheimer’s Disease and Epilepsy. Front Cell Neurosci. 2020;14:19. https://doi.org/10.3389/fncel.2020.00019
Liu Y, Chong E, Li X, et al. Astragaloside IV rescues MPP+-induced mitochondrial dysfunction through upregulation of methionine sulfoxide reductase A. Exp Ther Med. 2017;14(3):2650-2656. https://doi.org/10.3892/etm.2017.4834
Ben Y, Hao J, Zhang Z, et al. Astragaloside IV inhibits mitochondrial-dependent apoptosis of the dorsal root ganglion in diabetic peripheral neuropathy rats through modulation of the SIRT1/p53 signaling pathway. Diabetes Metab Syndr Obes. 2021;14:1647-1661. https://doi.org/10.2147/DMSO.S301068
Sun Q, Jia N, Wang W, et al. Protective effects of astragaloside IV against amyloid beta1-42 neurotoxicity by inhibiting the mitochondrial permeability transition pore opening. PloS One. 2014;9(6):e98866. https://doi.org/10.1371/journal.pone.0098866
Qu M, Zhou Z, Chen C, et al. Inhibition of mitochondrial permeability transition pore opening is involved in the protective effects of mortalin overexpression against beta-amyloid-induced apoptosis in SH-SY5Y cells. Neurosci Res. 2012;72(1):94-102. https://doi.org/10.1016/j.neures.2011.09.009
Chen W, Chan Y, Wan W, et al. Aβ1-42 induces cell damage via RAGE-dependent endoplasmic reticulum stress in bEnd.3 cells. Exp Cell Res. 2018;362(1):83-89. https://doi.org/10.1016/j.yexcr.2017.11.005
Ma Y, Xiong L. Astragaloside IV ameliorates endoplasmic reticulum stress-induced apoptosis of Aβ25-35-treated PC12 cells by inhibiting the p38 MAPK signaling pathway. Mol Med Rep. 2019;19(3):2005-2012. https://doi.org/10.3892/mmr.2019.9855
Gao ML, Zhang YD, Li N, et al. Bone marrow mesenchymal stem cells transplanted into a rat model of Alzheimer’s disease: improvement in the learning and memory ability. Zhongguo Zuzhi Gongcheng Yanjiu. 2016;20:2059-2065.
Sultana R, Banks WA, Butterfield DA. Decreased levels of PSD95 and two associated proteins and increased levels of BCl2 and caspase 3 in hippocampus from subjects with amnestic mild cognitive impairment: Insights into their potential roles for loss of synapses and memory, accumulation of Abeta, and neurodegeneration in a prodromal stage of Alzheimer’s disease. J Neurosci Res. 2010;88(3):469-477. https://doi.org/10.1002/jnr.22227
Wang X, Gao F, Xu W, et al. Depichering the effects of astragaloside IV on AD‐like phenotypes: a systematic and experimental investigation. Oxid Med Cell Longev. 2021;2021:1020614. https://doi.org/10.1155/2021/1020614
Schliebs R, Arendt T. The significance of the cholinergic system in the brain during aging and in Alzheimer’s disease. J Neural Transm (Vienna). 2006;113(11):1625-1644. https://doi.org/10.1007/s00702-006-0579-2
Colović MB, Krstić DZ, Lazarević-Pašti TD, et al. Acetylcholinesterase inhibitors: Pharmacology and toxicology. Curr Neuropharmacol. 2013;11(3):315-335. https://doi.org/10.2174/1570159X11311030006
Chang Y, Bai M, Zhang X, et al. Neuroprotective and acetylcholinesterase inhibitory activities of alkaloids from Solanum lyratum Thunb.: An in vitro and in silico analyses. Phytochemistry. 2023;209:113623. https://doi.org/10.1016/j.phytochem.2023.113623
Stępnik K, Kukula-Koch W, Plazinski W, et al. Significance of astragaloside IV from the roots of Astragalus mongholicus as an acetylcholinesterase inhibitor—From the computational and biomimetic analyses to the in vitro and in vivo studies of safety. Int J Mol Sci. 2023;24(11):9152. https://doi.org/10.3390/ijms24119152
Govindarajulu M, Pinky PD, Bloemer J, et al. Signaling mechanisms of selective PPARγ modulators in Alzheimer’s disease. PPAR Res. 2018;2018:2010675. https://doi.org/10.1155/2018/2010675
Michailidis M, Moraitou D, Tata DA, et al. Alzheimer’s disease as type 3 diabetes: common pathophysiological mechanisms between Alzheimer’s disease and type 2 diabetes. Int J Mol Sci. 2022;23(5):2687. https://doi.org/10.3390/ijms23052687
Landreth G, Jiang Q, Mandrekar S, et al. PPARγ agonists as therapeutics for the treatment of Alzheimer’s disease. Neurotherapeutics. 2008;5(3):481-489.
Wang X, Wang Y, Hu JP, et al. Astragaloside IV, a natural PPARγ agonist, reduces Aβ production in Alzheimer’s disease through inhibition of BACE1. Mol Neurobiol. 2017;54(4):2939-2949. https://doi.org/10.1007/s12035-016-9874-6
Wang X, Xu W, Chen H, et al. Astragaloside IV prevents Aβ1-42 oligomers-induced memory impairment and hippocampal cell apoptosis by promoting PPARγ/BDNF signaling pathway. Brain Res. 2020;1747:147041. https://doi.org/10.1016/j.brainres.2020.147041
Rodríguez JJ, Jones VC, Tabuchi M, et al. Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer’s Ddisease. PLoS ONE. 2008;3(8):e2935. https://doi.org/10.1371/journal.pone.0002935
Jin K, Peel AL, Mao XO, et al. Increased hippocampal neurogenesis in Alzheimer’s disease. Proc Natl Acad Sci U S A. 2004;101(1):343-347. https://doi.org/10.1073/pnas.2634794100
Haiyan H, Rensong Y, Guoqin J, et al. Effect of astragaloside IV on neural stem cell transplantation in Alzheimer’s disease rat models. Evid Based Complement Alternat Med. 2016;2016:3106980. https://doi.org/10.1155/2016/3106980
Yin Y, Yan L, Huang LQ, et al. Anti-apoptosis effect of astragaloside IV on Alzheimer’s disease rat model via enhancing the expression of Bcl-2 and Bcl-xl. Scand J Lab Anim Sci. 2010;37(2):75-82. https://doi.org/10.23675/sjlas.v37i2.206
Yu C, Zhang J, Li X, et al. Astragaloside IV-induced Nrf2 nuclear translocation ameliorates lead-related cognitive impairments in mice. Biochim Biophys Acta Mol Cell Res. 2021;1868(1):118853. https://doi.org/10.1016/j.bbamcr.2020.118853

Close metadata